NASDAQ : DARE
Daré Bioscience, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.6815 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 13.40M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 13.76M |
| Enterprise Value | 7.91M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 19.67M |
| Shares Outstanding | 19.67M |
| Shares Change (YoY) | +62.78% |
| Shares Change (QoQ) | +2.53% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 12.35% |
| Float | 17.36M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.07 |
| Forward PS | 2.99 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.99 |
| Quick Ratio | 0.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -39.29% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -203.95% |
| Weighted Average Cost of Capital (WACC) | 6.57% |
| Revenue Per Employee | $56,914 |
| Profits Per Employee | -$457,798 |
| Employee Count | 24 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.01 |
| 52-Week Price Change | -65.37% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 42.59 |
| Average Volume (20 Days) | 137,966 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.14M |
| Short Previous Month | 922,037 |
| Short % of Shares Out | 5.81% |
| Short % of Float | 6.59% |
| Short Ratio (days to cover) | 5.59 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.37M |
| Gross Profit | 3.33M |
| Operating Income | -11.11M |
| Pretax Income | -10.99M |
| Net Income | -10.99M |
| EBITDA | -8.98M |
| EBIT | -11.11M |
| Loss Per Share | -$0.78 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 12.62M |
| Total Debt | 6.76M |
| Net Cash | 5.85M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | -560,100 |
| Book Value Per Share | -0.04 |
| Working Capital | -236,457 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.29M |
| Capital Expenditures | -461,929 |
| Depreciation & Amortization | 2.13M |
| Net Borrowing | -2.15M |
| Free Cash Flow | -11.76M |
| FCF Per Share | -$0.60 |
Margins
| Measure | Value |
|---|
| Gross Margin | 243.91% |
| Operating Margin | -813.38% |
| Pretax Margin | -804.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -62.78% |
| Shareholder Yield | -62.78% |
| Earnings Yield | -111.19% |
| FCF Yield | -85.43% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.33 |
| Price Target Difference | 805.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 199.57% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -13.06 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |